company background image
HG6 logo

Mayne Pharma Group DB:HG6 Stock Report

Last Price

€2.78

Market Cap

€231.0m

7D

-4.1%

1Y

-28.0%

Updated

22 Dec, 2024

Data

Company Financials +

Mayne Pharma Group Limited

DB:HG6 Stock Report

Market Cap: €231.0m

HG6 Stock Overview

A specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. More details

HG6 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Mayne Pharma Group Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Mayne Pharma Group
Historical stock prices
Current Share PriceAU$2.78
52 Week HighAU$4.44
52 Week LowAU$2.18
Beta1.25
1 Month Change3.73%
3 Month Change0%
1 Year Change-27.98%
3 Year Change-13.66%
5 Year Change-50.36%
Change since IPO-62.43%

Recent News & Updates

Recent updates

Shareholder Returns

HG6DE PharmaceuticalsDE Market
7D-4.1%-2.5%-2.6%
1Y-28.0%-15.6%6.9%

Return vs Industry: HG6 underperformed the German Pharmaceuticals industry which returned -15.6% over the past year.

Return vs Market: HG6 underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is HG6's price volatile compared to industry and market?
HG6 volatility
HG6 Average Weekly Movement7.5%
Pharmaceuticals Industry Average Movement5.4%
Market Average Movement4.8%
10% most volatile stocks in DE Market11.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: HG6's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: HG6's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2005n/aShawn O’Brienwww.maynepharma.com

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through three segments: Women’s Health, Dermatology, and International. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women’s health, and infectious disease therapeutic areas.

Mayne Pharma Group Limited Fundamentals Summary

How do Mayne Pharma Group's earnings and revenue compare to its market cap?
HG6 fundamental statistics
Market cap€231.05m
Earnings (TTM)-€101.07m
Revenue (TTM)€232.81m

1.0x

P/S Ratio

-2.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HG6 income statement (TTM)
RevenueAU$388.40m
Cost of RevenueAU$169.62m
Gross ProfitAU$218.78m
Other ExpensesAU$387.39m
Earnings-AU$168.62m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.08
Gross Margin56.33%
Net Profit Margin-43.41%
Debt/Equity Ratio7.0%

How did HG6 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 12:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mayne Pharma Group Limited is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightAPP Securities Pty Ltd.
Russell WrightBarclay Pearce Capital Pty Limited
John HesterBell Potter